MX9706267A - Antigeno de helicobacter pylori. - Google Patents

Antigeno de helicobacter pylori.

Info

Publication number
MX9706267A
MX9706267A MX9706267A MX9706267A MX9706267A MX 9706267 A MX9706267 A MX 9706267A MX 9706267 A MX9706267 A MX 9706267A MX 9706267 A MX9706267 A MX 9706267A MX 9706267 A MX9706267 A MX 9706267A
Authority
MX
Mexico
Prior art keywords
helicobacter pylori
antigen
pylori antigen
novel
antigenic fragments
Prior art date
Application number
MX9706267A
Other languages
English (en)
Other versions
MXPA97006267A (es
Inventor
Christopher John Smith
Robert Llwellyn Clancy
Allan Cripps
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of MX9706267A publication Critical patent/MX9706267A/es
Publication of MXPA97006267A publication Critical patent/MXPA97006267A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K2039/106Vibrio; Campylobacter; Not used, see subgroups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se provee un antígeno novedoso para H. pylori. También se describe el uso en el diagnostico de infeccion por H. pylori incluyendo métodos para dicha diagnosis, y equipos para utilizar dicho método. Además, se proveen fragmentos antigénicos novedosos del antígeno, así como vacunas que comprenden ya sea el antígeno o uno o más fragmentos antigénicos.
MXPA/A/1997/006267A 1995-02-15 1997-08-15 Antigeno de helicobacter pylori MXPA97006267A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9502899.9A GB9502899D0 (en) 1995-02-15 1995-02-15 Novel antigen
GB9502899.9 1995-02-15
PCT/GB1996/000351 WO1996025430A1 (en) 1995-02-15 1996-02-15 Helicobacter pylori antigen

Publications (2)

Publication Number Publication Date
MX9706267A true MX9706267A (es) 1997-11-29
MXPA97006267A MXPA97006267A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
WO1996025430A1 (en) 1996-08-22
JPH11503999A (ja) 1999-04-06
DE69615537D1 (en) 2001-10-31
ES2164231T3 (es) 2002-02-16
KR19980701698A (ko) 1998-06-25
DE69615537T2 (de) 2002-04-18
IL117151A (en) 2001-06-14
PT809653E (pt) 2002-03-28
ATE206138T1 (de) 2001-10-15
IL117151A0 (en) 1996-06-18
EP0809653A1 (en) 1997-12-03
NZ301334A (en) 1999-08-30
FI973335A0 (fi) 1997-08-14
NO973753D0 (no) 1997-08-14
FI973335A (fi) 1997-08-14
DK0809653T3 (da) 2001-11-19
NO973753L (no) 1997-08-14
AU4672896A (en) 1996-09-04
CA2212952A1 (en) 1996-08-22
GB9502899D0 (en) 1995-04-05
AU714222B2 (en) 1999-12-23
CN1175955A (zh) 1998-03-11
ZA9601216D (en) 1997-09-15
EP0809653B1 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
GB2303855B (en) Helicobacter pylori antigenic protein preparation and immunoassays
EP1170368A3 (en) Immunization by inoculation of dna transcription unit
ES8705522A1 (es) Un procedimiento para la preparacion de derivados purificados de una glicoproteina.
DE69332643D1 (de) Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus
IL142948A0 (en) Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
WO1999042588A3 (en) Group b streptococcus antigens
EP0771214A4 (en) TREATMENT AND PREVENTION OF HELICOBACTER INFECTIONS
NZ314585A (en) Method of treating H. Pylori associated gastroduodenal disease
HK1004677A1 (en) Antigenic preparation for treatment or prevention of helicobacter infection
NZ331557A (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
EP0283840A3 (en) Mycoplasma hyopneumoniae antigen and uses therefor
WO2002054073A3 (en) Latent human tuberculosis model, diagnostic antigens, and methods of use
DE69615537D1 (en) Helicobacter pylori antigen
DE244295T1 (de) Aus weichtieren isoliertes immunogen, verfahren zur herstellung desselben, diagnostische reagenzien fuer menschliche bilharziosen, impfstoffe gegen schistosomiasis und immunisierende zubereitungen, die dieses immunogen enthalten.
MX9802486A (es) Proteina de helicobacter pylori.
MX9700215A (es) Proteinas y vacunas de helicobacter.
AU6162794A (en) Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor